United Therapeutics has been closely monitoring the rapidly evolving situation around Coronavirus (COVID-19). We are dedicated to providing ongoing support for patients and healthcare providers, and ensuring an uninterrupted supply of drug product.

Request a rep

Thank you for your interest in Remodulin

If you would like to speak with a United Therapeutics Representative, please fill out the form and click submit, and someone will contact you shortly.

*Required field.

Privacy

United Therapeutics respects your right to have your personal information kept private. We may use this information to send you materials on our products and services that may be of interest to you. We will not share your information with any third parties or outside mailing lists.

By submitting this registration, I understand that I am giving United Therapeutics Corporation and its affiliates and business partners permission to use my personal information to provide me with information and offers related to support programs, treatment options, services, and opportunities to participate in market research provided by United Therapeutics. I understand that United Therapeutics and its contractors will not sell or rent my personal information. I understand I may revoke my permission at any time by clicking on the unsubscribe link at the bottom of the page.

For more information about how United Therapeutics will use and protect your personal information, please read the Privacy Policy.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).